Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Acromegaly — 90 mg deep SC q4wk initially, titrated based on GH/IGF-1 (range 60–120 mg). The labeled starting dose is 90 mg; the 60–120 mg range reflects dose adjustments, not the full approved range. GEP-NET — 120 mg deep SC q4wk. Carcinoid syndrome — 120 mg deep SC q4wk. Administered into the superior external gluteal area by a healthcare professional.